Skip to main content

Table 2 Patient disposition

From: Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

 

Asian patients

Non-Asian patients

Pazopanib

Sunitinib

Pazopanib

Sunitinib

Study discontinuation, n (%)

146 (78)

139 (79)

320 (92)

331 (93)

Died, n (%)

66 (35)

59 (33)

171 (49)

190 (53)

  1. At data cutoff (May 21, 2012)
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us